Inogen (NASDAQ: INGN) and Palomar Medical Technologies (NASDAQ:PMTI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
This table compares Inogen and Palomar Medical Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Palomar Medical Technologies||N/A||N/A||N/A|
This is a breakdown of current recommendations for Inogen and Palomar Medical Technologies, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Palomar Medical Technologies||0||0||0||0||N/A|
Inogen currently has a consensus target price of $98.50, suggesting a potential downside of 13.76%. Given Inogen’s higher probable upside, research analysts clearly believe Inogen is more favorable than Palomar Medical Technologies.
Valuation and Earnings
This table compares Inogen and Palomar Medical Technologies’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Inogen||$202.83 million||11.75||$20.51 million||$1.43||79.87|
|Palomar Medical Technologies||N/A||N/A||N/A||($0.27)||-49.67|
Inogen has higher revenue and earnings than Palomar Medical Technologies. Palomar Medical Technologies is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Inogen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Palomar Medical Technologies has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.
Inogen beats Palomar Medical Technologies on 9 of the 10 factors compared between the two stocks.
Inogen Company Profile
Inogen, Inc. is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device. Its three portable product offerings, the Inogen One G4, Inogen One G3 and Inogen One G2, at approximately 2.8, 4.8 and 7.0 pounds with a single battery, respectively. Its Inogen One G4, Inogen One G3 and Inogen One G2 are sub-3, sub-5 and sub-10 pound portable oxygen concentrators, respectively. All of its Inogen One systems are equipped with Intelligent Delivery Technology. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory oxygen patient market and serves as a backup to its Inogen One system for ambulatory patients on its rental service.
Palomar Medical Technologies Company Profile
Palomar Medical Technologies, Inc. (Palomar) is a researcher and developer of aesthetic light-based systems for hair removal and other cosmetic procedures, including both lasers and high powered lamps. The Company offers a range of products based on technologies that include, but are not limited to: hair removal; body sculpting, including laser-assisted liposuction; removal of vascular lesions, such as rosacea, spider veins, port wine stains and hemangiomas; wrinkle reduction; removal of leg veins; removal of benign pigmented lesions, such as age and sun spots, freckles and melasma; tattoo removal; acne treatment; skin resurfacing, pseudofolliculitis barbae (PFB) treatment; treatment of red pigmentation in hypertrophic and keloid scars; treatment of verrucae, skin tags and seborrheic keratosis; skin tightening through soft tissue coagulation; scars, and other skin treatments. In June 2013, Cynosure Inc announced the completion of its acquisition of Palomar Medical Technologies Inc.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.